Naoyuki Kamatani, MD, PhD
Chief Executive Officer
Naoyuki Kamatani founded EnePharma Inc. in 2019 and has been Director of StaGen Co., Ltd. (Japan) since 2008.
Dr. Naoyuki Kamatani has extensive experience in genetics, drug R&D, and translational research. He worked with Dennis A Carson on research of MTAP deficiency in human cancers and proposed the first personalized anti-cancer therapy in the world. He led the clinical development of the anti-gout drug feuboxostat developed by Teijin Pharma, Japan. Recently, he has developed a conceptual framework called the “Six-layer structure for genomics” (Kamatani N. Six-layer structure for genomics and its applications. J Hum Genet 2016 Mar;61:267-270.) to facilitate identification of genes that impact human phenotypes and diseases, potentially leading to novel therapeutic targets. This framework along with the deep consideration into the relationship between entropy and energy in biology led to development of the ATP enhancing drug that is being developed by EnePharma Inc.
Previous affiliations: Director of the Laboratory for Statistical Analysis at the RIKEN Center for Genomic Medicine (CGM) from 2003 to 2011, Director of CGM, RIKEN from 2010 to 2011 and Professor of the Institute of Rheumatology at Tokyo Women’s Medical University from 1996 to 2008.
Yoshi Shima, LL.M.
Chief Officer, Legal & IP
Secretary at EnePharma, Inc. concurrent with Executive Officer in charge of Legal & IP at StaGen Co., Ltd., the parent company of EnePharma. He has been working as a corporate counsel and negotiator at several business entities, such fields as pharmaceutical, semiconductor, chemical, IT and banking. Concurrently with Head of Business Risk Management Office at MTI Ltd. (Tier 1 at TSE: 9438)
Previous affiliations: Head of Corporate Reorganization Office, Elpida Mermoy, Inc.; Head of Legal Office, Nihon Schering K.K.; and Corporate Counsel, Polyplastics Co., Ltd.